Galectin Therapeutics (GALT) Cash from Financing Activities (2010 - 2026)
Galectin Therapeutics (GALT) posted quarterly Cash from Financing Activities of $257000.0 for Q1 2026, down 97.9% quarter-over-quarter from $12.2 million in Q4 2025.
Galectin Therapeutics (GALT) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $257000.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities changed N/A year-over-year to $257000.0; the TTM figure through Mar 2026 stood at $26.7 million (up 25.93% YoY), while the FY2025 annual figure was $26.5 million, down 15.22% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $257000.0, down from $12.2 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $12.9 million in Q2 2025, with the low at $257000.0 in Q1 2026.
- The 5-year median for Cash from Financing Activities is $10.0 million (2022), against an average of $8.3 million.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities plunged 91.49% in 2024, then jumped 1337.96% in 2025.
- Galectin Therapeutics' Cash from Financing Activities stood at $10.0 million in 2022, then changed by 0.0% to $10.0 million in 2023, then slumped by 91.49% to $851000.0 in 2024, then surged by 1337.96% to $12.2 million in 2025, then plunged by 97.9% to $257000.0 in 2026.
- Business Quant data shows GALT's Cash from Financing Activities at $257000.0 in Q1 2026, $12.2 million in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Galectin Therapeutics | 226.55 Mn | 226.55 Mn | - | 257,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 257,000.00 |
| Mar 31, 2026 | 257,000.00 |
| Dec 31, 2025 | 12.24 Mn |
| Dec 31, 2025 | 12.24 Mn |
| Sep 30, 2025 | 1.30 Mn |
| Sep 30, 2025 | 1.30 Mn |
| Jun 30, 2025 | 12.94 Mn |
| Jun 30, 2025 | 12.94 Mn |
| Dec 31, 2024 | 851,000.00 |
| Dec 31, 2024 | 851,000.00 |
| Sep 30, 2024 | 10.00 Mn |
| Sep 30, 2024 | 10.00 Mn |
| Jun 30, 2024 | 10.38 Mn |
| Jun 30, 2024 | 10.38 Mn |
| Mar 31, 2024 | 10.00 Mn |
| Mar 31, 2024 | 10.00 Mn |
| Dec 31, 2023 | 10.00 Mn |
| Dec 31, 2023 | 10.00 Mn |
| Sep 30, 2023 | 10.03 Mn |
| Sep 30, 2023 | 10.03 Mn |